Document is current
Any future updates will be listed below
-
Authors
Ciecko, Claudius
Okut, Hayrettin
Lancaster, Brent
Schwasinger-Schmidt, Tiffany
- License Information
-
More Information
Article History
Received: 6 February 2023
Accepted: 15 July 2023
First Online: 21 July 2023
Declarations
:
: This project received IRB approval and the authors have the following disclosures:Tiffany Schwasinger-Schmidt, MD, PhD has conducted clinical trials research as principal investigator for the following pharmaceutical companies over the last twelve months:1. Allergan2. Eisai3. Lundbeck4. Janssen5. SAGE pharmaceuticals6. Sarepta7. Corcept8. Boehringer Ingelheim9. NIAID10. Astra Zeneca11. Sanofi12. Axsome13. NIH14. PCORI15. Johnson and Johnson16. Moderna17. OrganonAll clinical trial and study contracts were with and payments were made to the University of Kansas Medical Center Research Institute, which is a research institute affiliated with Kansas University School of Medicine-Wichita (KUSM-W).Authors Claudius Ciecko, MS4, Hayrettin Okut, PhD, and Brent Lancaster, MD, FACS, FASMBS have no disclosures.
